Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy of Sacral Nerve Stimulation Before Definitive Implantation (SNStest)
This study is not yet open for participant recruitment.
Verified by University of Lausanne Hospitals, August 2007
Sponsored by: University of Lausanne Hospitals
Information provided by: University of Lausanne Hospitals
ClinicalTrials.gov Identifier: NCT00522691
  Purpose

Sacral nerve stimulation (SNS) is an emerging treatment for patients with severe faecal incontinence. The test stimulation is minimally invasive, associated to low morbidity and relatively cheap. On the contrary, implantation of the definite stimulator is related to higher morbidity and considerable costs. A careful patent selection for definite implantation is therefore crucial. However, indication for implantation is actually based only on the subjective criteria reported in the patients´ diary only. Patients and care providers are likely to overestimate the real effect of SNS leading to an unjustified overuse of this expensive device. It is therefore necessary to evaluate real efficacy of SNS during the testing phase in a unbiased setting in order to avoid unnecessary morbidity and costs.


Condition Intervention
Fecal Incontinence
Procedure: sacral nerve stimulation

MedlinePlus related topics: Urinary Incontinence
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study
Official Title: Efficacy of Sacral Nerve Stimulation Before Definitive Implantation: a Multicenter Randomized, Double Blind, Crossover Trial

Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:
  • Primary success rate of SNS after 7 days. By convention this is assessed by >50% reduction in the number of episodes in the symptom diary. [ Time Frame: 24 months ]

Estimated Enrollment: 34
Study Start Date: September 2007
Arms Assigned Interventions
A: Experimental
Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
Procedure: sacral nerve stimulation
B: Experimental
Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
Procedure: sacral nerve stimulation

Detailed Description:

Sacral nerve stimulation (SNS) is an emerging treatment for patients with severe faecal incontinence when conservative measures fail and surgical repair is not indicated. In a minimally-invasive approach and under local anaesthesia, an electrode is placed around sacral nerve root S2-4 and electrical stimulation is applied to the sacral spinal nerves. Effectiveness of SNS is definitively not only explained by placebo effect but the pathophysiologic mechanisms remain unclear. Suggested pathways include modulation of afferent nerve fibres and direct stimulation of the pelvic floor and anal sphincter muscle. After placement of the electrode, the patient is stimulated by an external stimulator for 1-3 weeks. During this period, the patient documents the number of faecal incontinence episodes or urgencies in a symptom diary. By convention, indication for permanent stimulation is based on a 50% reduction in the number of episodes. After a successful testing period, the permanent stimulator is implanted, generally in the upper gluteal region.

Previous studies report success rates up to 80%. The only randomized trial with a proper sample size evaluated the efficacy of SNS after definite implantation. In this study, 63% of the patients felt improved during the placebo period and might not really benefit from the device. The real success rate of SNS is therefore likely to be considerably lower. Efficacy of SNS during the testing phase has never been assessed in a blinded randomized study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients admitted to SNS test for treatment of faecal incontinence after unsuccessful conservative (or surgical) treatment.

Exclusion criteria:

  • Absence of informed consent.
  • Patients not speaking french or german.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522691

Contacts
Contact: Martin Hubner, MD +41213142418 martin.hubner@chuv.ch
Contact: Yannick Cerantola, MD +41213142383 yannick.cerantola@chuv.ch

Locations
Switzerland, Vaud
Visceral surgery, university hospital
Lausanne, Vaud, Switzerland, 1005
Sponsors and Collaborators
University of Lausanne Hospitals
Investigators
Principal Investigator: Martin Hubner, MD Visceral Surgery, University Lausanne, Switzerland
Study Director: Jean-Claude Givel, Professor Visceral Surgery, University Lausanne, Switzerland
Study Chair: Nicolas Demartines, Professor Visceral Surgery, University Lausanne, Switzerland
  More Information

Study ID Numbers: CHV120/07
Study First Received: August 28, 2007
Last Updated: August 28, 2007
ClinicalTrials.gov Identifier: NCT00522691  
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Lausanne Hospitals:
Fecal incontinence, sacral nerve stimulation

Study placed in the following topic categories:
Signs and Symptoms
Fecal Incontinence
Digestive System Diseases
Urologic Diseases
Urination Disorders
Gastrointestinal Diseases
Urinary Incontinence
Intestinal Diseases
Rectal Diseases

Additional relevant MeSH terms:
Urological Manifestations

ClinicalTrials.gov processed this record on January 16, 2009